Patents by Inventor Ellen Chi

Ellen Chi has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • MATERIALS AND METHODS OF MAKING OR USING IL-23R BINDING PROTEINS
    Publication number: 20250179196
    Abstract: The present invention relates to monoclonal anti-interleukin-23 receptor (IL-23R) antibodies, nucleic acids and expression vectors encoding the antibodies, recombinant cells containing the vectors, and corresponding compositions and methods of making and using antibodies respectively, i.e., e.g., detecting, selecting, enriching, inhibiting, or antagonizing IL-23R or treat an autoimmune or inflammatory diseases or disorders.
    Type: Application
    Filed: August 1, 2022
    Publication date: June 5, 2025
    Inventors: Qiang Chen, Ellen Chi, Wilson Edwards, Carrie N. Greving, Ann LaCombe, Xinyi Li, Wai Lin
  • IMMUNOGLOBULINS AND USES THEREOF
    Publication number: 20250026803
    Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
    Type: Application
    Filed: October 2, 2024
    Publication date: January 23, 2025
    Inventors: Mark MACIELAG, Raymond J. PATCH, Rui ZHANG, Martin A. CASE, Mark J. WALL, Yue-Mei ZHANG, Shamina M. RANGWALA, James N. LEONARD, Raul C. CAMACHO, Michael J. HUNTER, Katharine E. D'AQUINO, Wilson EDWARDS, Ronald V. SWANSON, Wenying JIAN, Ellen CHI
  • Anti-idiotypic antibodies against anti-KLK2 antibodies
    Patent number: 12162951
    Abstract: In certain aspects, the disclosure relates to anti-idiotype antibodies and antigen-binding portions thereof that specifically bind a KL2B413 containing protein, e.g., an antibody or antigen-binding portions thereof. In some aspects, the anti-idiotype antibodies and antigen-binding portions of the present disclosure can be used in methods to detect and quantify cells expressing chimeric antigen receptors that include KL2B413.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: December 10, 2024
    Assignee: Janssen Biotech, Inc.
    Inventors: Zemeda Ainekulu, Qiang Chen, Ellen Chi, Wilson Edwards, Matt Husovsky, Ann Lacombe, Quynh Nguyen, Paul H. Kim, H. Mimi Zhou, John T. Lee
  • Immunoglobulins and uses thereof
    Patent number: 12134636
    Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
    Type: Grant
    Filed: October 30, 2020
    Date of Patent: November 5, 2024
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Mark J. Wall, Yue-Mei Zhang, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Ellen Chi
  • Anti-idiotypic antibodies against anti-GPRC5D antibodies
    Patent number: 12030937
    Abstract: In certain aspects, the disclosure relates to anti-idiotype antibodies and antigen-binding portions thereof that specifically bind a GP5B83 containing protein, e.g., an antibody or antigen-binding portions thereof. In some aspects, the anti-idiotype antibodies and antigen-binding portions of the present disclosure can be used in methods to detect and quantify cells expressing chimeric antigen receptors that include GP5B83.
    Type: Grant
    Filed: July 15, 2021
    Date of Patent: July 9, 2024
    Assignee: Janssen Biotech, Inc.
    Inventors: Ellen Chi, Wilson Edwards, Matt Husovsky, Ann Lacombe, Christian Martinez, H. Mimi Zhou, John T. Lee
  • MOLECULES WITH ENGINEERED ANTIBODY CONSTANT REGION VARIANTS
    Publication number: 20240218083
    Abstract: A binding molecule comprising (i) a first polypeptide comprising a heavy chain variable region (VH) and a region derived from the first constant region of an antibody heavy chain (CH1), and (ii) a second polypeptide comprising a light chain variable region (VL) and a region derived from the constant region of an antibody light chain (CL), wherein the region derived from the CH1 region and/or the region derived from the CL region comprises one or more antigen binding loop(s).
    Type: Application
    Filed: April 18, 2022
    Publication date: July 4, 2024
    Inventors: Sanjaya SINGH, Ellen CHI, Martin CASE, Hong Mimi ZHOU, Linus HYUN, Jennifer FURMAN, Ann LACOMBE
  • GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF
    Publication number: 20240117000
    Abstract: The present invention comprises conjugates comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Application
    Filed: August 31, 2023
    Publication date: April 11, 2024
    Inventors: Yue-Mei ZHANG, Raul CAMACHO, Martin A. CASE, Ellen CHI, Suzanne EDAVETTAL, Wilson EDWARDS, Lisa NORQUAY, Mark J. WALL, Rui ZHANG, Songmao ZHENG
  • ANTIBODY-COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE COMPOUNDS AS MODULATORS OF NEUROPEPTIDE Y RECEPTORS
    Publication number: 20230365644
    Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Application
    Filed: January 12, 2023
    Publication date: November 16, 2023
    Inventors: Mark MACIELAG, Raymond J. PATCH, Rui ZHANG, Martin A. CASE, Shamina M. RANGWALA, James N. LEONARD, Raul C. CAMACHO, Michael J. HUNTER, Katharine E. D'AQUINO, Wilson EDWARDS, Ronald V. SWANSON, Wenying JIAN, Yue-Mei ZHANG, Mark WALL, Ellen CHI
  • Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
    Patent number: 11780900
    Abstract: The present invention comprises conjugates comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: October 10, 2023
    Assignee: Janssen Sciences Ireland Unlimited Company
    Inventors: Yue-Mei Zhang, Raul Camacho, Martin A. Case, Ellen Chi, Suzanne Edavettal, Wilson Edwards, Lisa Norquay, Mark J. Wall, Rui Zhang, Songmao Zheng
  • Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors
    Patent number: 11767354
    Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Grant
    Filed: February 5, 2021
    Date of Patent: September 26, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Yue-Mei Zhang, Mark J. Wall, Ellen Chi
  • PSMA binding agents and uses thereof
    Patent number: 11746157
    Abstract: The present invention relates to antibodies specifically binding PSMA or PSMA and CD3, polynucleotides encoding the antibodies or fragments, and methods of making and using the foregoing.
    Type: Grant
    Filed: May 21, 2019
    Date of Patent: September 5, 2023
    Assignee: JANSSEN BIOTECH, INC.
    Inventors: Glenn Mark Anderson, Tammy Bush, Rosa Maria Fernandes Cardoso, Ellen Chi, Judith Ann Connor, Thai Quang Dinh, Derrick Lemon Domingo, John Michael Jones, Colleen Kane, Bethany Kay Mattson, Theresa Marie McDevitt, Jill Marie Mooney, Richard Stephen Tawadros, Hong Mimi Zhou
  • Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors
    Patent number: 11591379
    Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Grant
    Filed: March 16, 2020
    Date of Patent: February 28, 2023
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Yue-Mei Zhang, Mark J. Wall, Ellen Chi
  • Immunoglobulins and uses thereof
    Patent number: 11401315
    Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
    Type: Grant
    Filed: August 21, 2020
    Date of Patent: August 2, 2022
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Yue-Mei Zhang, Mark J. Wall, Ellen Chi
  • ANTI-IDIOTYPIC ANTIBODIES AGAINST ANTI-KLK2 ANTIBODIES
    Publication number: 20220064334
    Abstract: In certain aspects, the disclosure relates to anti-idiotype antibodies and antigen-binding portions thereof that specifically bind a KL2B413 containing protein, e.g., an antibody or antigen-binding portions thereof. In some aspects, the anti-idiotype antibodies and antigen-binding portions of the present disclosure can be used in methods to detect and quantify cells expressing chimeric antigen receptors that include KL2B413.
    Type: Application
    Filed: July 15, 2021
    Publication date: March 3, 2022
    Inventors: Zemeda AINEKULU, Qiang CHEN, Ellen CHI, Wilson EDWARDS, Matt HUSOVSKY, Ann LACOMBE, Quynh NGUYEN, Paul H. KIM, H. Mimi ZHOU, John T. LEE
  • ANTI-IDIOTYPIC ANTIBODIES AGAINST ANTI-GPRC5D ANTIBODIES
    Publication number: 20220064284
    Abstract: In certain aspects, the disclosure relates to anti-idiotype antibodies and antigen-binding portions thereof that specifically bind a GP5B83 containing protein, e.g., an antibody or antigen-binding portions thereof. In some aspects, the anti-idiotype antibodies and antigen-binding portions of the present disclosure can be used in methods to detect and quantify cells expressing chimeric antigen receptors that include GP5B83.
    Type: Application
    Filed: July 15, 2021
    Publication date: March 3, 2022
    Inventors: Ellen CHI, Wilson EDWARDS, Matt HUSOVSKY, Ann LACOMBE, Christian MARTINEZ, H. Mimi ZHOU, John T. LEE
  • GLUCAGON LIKE PEPTIDE 1 (GLP-1) FUSION PEPTIDE COUPLED CYCLIC PEPTIDE TYROSINE TYROSINE CONJUGATES AND USES THEREOF
    Publication number: 20210253661
    Abstract: The present invention comprises conjugates comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Application
    Filed: April 24, 2019
    Publication date: August 19, 2021
    Inventors: Yue-Mei ZHANG, Raul CAMACHO, Martin A. CASE, Ellen CHI, Suzanne EDAVETTAL, Wilson EDWARDS, Lisa NORQUAY, Mark J. WALL, Rui ZHANG, Songmao ZHENG
  • Antibody-Coupled Cyclic Peptide Tyrosine Tyrosine Compounds as Modulators of Neuropeptide Y Receptors
    Publication number: 20210163566
    Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Application
    Filed: February 5, 2021
    Publication date: June 3, 2021
    Inventors: Mark MACIELAG, Raymond J. PATCH, Rui ZHANG, Martin A. CASE, Shamina M. RANGWALA, James N. LEONARD, Raul C. CAMACHO, Michael J. HUNTER, Katharine E. D'AQUINO, Wilson EDWARDS, Ronald V. SWANSON, Wenying JIAN, Yue-Mei ZHANG, Mark J. WALL, Ellen CHI
  • Antibody-coupled cyclic peptide tyrosine tyrosine compounds as modulators of neuropeptide Y receptors
    Patent number: 10968265
    Abstract: The present invention comprises conjugates comprising a monoclonal antibody conjugated to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Grant
    Filed: October 26, 2017
    Date of Patent: April 6, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Mark Macielag, Raymond J. Patch, Rui Zhang, Martin A. Case, Shamina M. Rangwala, James N. Leonard, Raul C. Camacho, Michael J. Hunter, Katharine E. D'Aquino, Wilson Edwards, Ronald V. Swanson, Wenying Jian, Yue-Mei Zhang, Mark J. Wall, Ellen Chi
  • IMMUNOGLOBULINS AND USES THEREOF
    Publication number: 20210094998
    Abstract: The present invention relates to a monoclonal antibody platform designed to be coupled to therapeutic peptides to increase the half-life of the therapeutic peptide in a subject. The invention also relates to pharmaceutical compositions and methods for use thereof.
    Type: Application
    Filed: October 30, 2020
    Publication date: April 1, 2021
    Inventors: Mark MACIELAG, Raymond J. PATCH, Rui ZHANG, Martin A. CASE, Mark J. WALL, Yue-Mei ZHANG, Shamina M. RANGWALA, James N. LEONARD, Raul C. CAMACHO, Michael J. HUNTER, Katharine E. D'AQUINO, Wilson EDWARDS, Ronald V. SWANSON, Wenying JIAN, Ellen CHI
  • Glucagon like peptide 1 (GLP-1) fusion peptide coupled cyclic peptide tyrosine tyrosine conjugates and uses thereof
    Patent number: 10875902
    Abstract: The present invention comprises conjugates comprising a glucagon-like peptide 1 (GLP-1) fusion peptide coupled to a cyclic PYY peptide. The invention also relates to pharmaceutical compositions and methods for use thereof. The novel conjugates are useful for preventing, treating or ameliorating diseases and disorders disclosed herein.
    Type: Grant
    Filed: April 24, 2019
    Date of Patent: December 29, 2020
    Assignee: Janssen Pharmaceutica NV
    Inventors: Yue-Mei Zhang, Raul C. Camacho, Martin A. Case, Ellen Chi, Suzanne Edavettal, Wilson Edwards, Lisa Norquay, Mark J. Wall, Rui Zhang, Songmao Zheng